Further evidence for a role of tumor CD200 expression in breast cancer metastasis: Decreased metastasis in CD200R1KO mice or using CD200-silenced EMT6

Breast Cancer Research and Treatment

Volumn 136, Issue 1, 2012, Pages 117-127

  Podnos, Anna ^a   Clark, David A ^a,b,c   Erin, Nuray ^a   Yu, Kai ^a   Gorczynski, Reginald M ^a,c  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Breast cancer; CD200R1KO; CD200shRNA; Immunotherapy; Metastasis

Indexed keywords

CD200 ANTIGEN; LENTIVIRUS VECTOR; MONOCLONAL ANTIBODY; SHORT HAIRPIN RNA;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CONTROLLED STUDY; DRAINING LYMPH NODE; DRUG CYTOTOXICITY; FEMALE; GENE SILENCING; GENETIC TRANSDUCTION; IMMUNE DEFICIENCY; KNOCKOUT MOUSE; LYMPH NODE; LYMPH NODE METASTASIS; METASTASIS INHIBITION; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; VIRAL GENE DELIVERY SYSTEM;

EID: 84867873656     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2258-3     Document Type: Article

References (34)

1. Pandit TS, Kennette W, MacKenzie L et al (2009) Lymphatic metastasis of breast cancer cells is associated with differential gene expression profiles that predict cancer stem cell- like properties and the ability to survive, establish and grow in a foreign environment. Int J Oncol 35:297-308
2. Pfeffer U, Romeo F, Noonan DM, Albini A (2009) Prediction of breast cancer metastasis by genomic profiling: where do we stand? Clin Exp Metastas 26:547-558
3. Chen XP, Xu ZT, Wang YT (2011) Recent advances in breast cancer metastasis suppressor 1. Int J Biol Marker 26:1-8
4. Pollard JW (2008) Macrophages define the invasive microenvironment in breast cancer. J Leukocyte Biol 84:623-630
5. Olkhanud PB, Damdinsuren B, Bodogai M et al (2011) Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4(+) T cells to T-regulatory cells. Cancer Res 71:3505-3515
6. Lu X, Kang YB (2009) Chemokine (C-C motif) ligand 2 engages CCR2(+) stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. J Biol Chem 284:29087-29096
7. Chen T, Jackson CR, Link A et al (2006) Int7G24A variant of transforming growth factor-beta receptor type 1 is associated with invasive breast cancer. Clin Cancer Res 12:392-397
8. Liang ZX, Yoon YH, Votaw J, Goodman MM, Williams L, Shim H (2005) Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 65:967-971
9. Takahashi M, Miyazaki H, Furihata M et al (2009) Chemokine CCL2/MCP-1 negatively regulates metastasis in a highly bone marrow-metastatic mouse breast cancer model. Clin Exp Metastas 26:817-828
10. Ma XR, Norsworthy K, Kundu N et al (2009) CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Mol Cancer Ther 8:490-498
11. Chen JQ, Yao YD, Gong C et al (2011) CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell 19:541-555
12. Huang B, Pan PY, Li QS et al (2006) Gr-1(+)CD115(+) immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66:1123-1131
13. Yang L, Debusk LM, Fukuda K et al (2004) Expansion of myeloid immune suppressor GR1+CD11b+cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6:409-421
14. Qin FXF (2009) Dynamic Behavior and Function of Foxp3(+) Regulatory T Cells in Tumor Bearing Host. Cell Mol Immunol 6:3-13
15. Yang L, Huang JH, Ren XB et al (2008) Abrogation of TGF beta signaling in mammary carcinomas recruits Gr- 1 + CD11b + myeloid cells that promote metastasis. Cancer Cell 13:23-35
16. Petermann KB, Rozenberg GI, Zedek D et al (2007) CD200 is induced by ERK and is a potential therapeutic target in melanoma. J Clin Invest 117:3922-3929
17. Siva A, Xin H, Qin F, Oltean D, Bowdish KS, Kretz-Rommel A (2008) Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200 Cancer Immunol. Immunotherapy 57:987-996
18. Moreaux J, Hose D, Reme T et al (2006) CD200 is a new prognostic factor in multiple myeloma. Blood 108:4194-4197
19. McWhirter JR, KretzRommel A, Saven A et al (2006) Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Nat Acad Sci USA 103:1041-1046
20. Tonks A (2007) CD200 as a prognostic factor in acute myeloid leukemia. Leukemia 21:566-568
21. Kawasaki BT, Mistree T, Hurt EM, Kalathur M, Farrar WL (2007) Co-expression of the tolerogenic glycoprotein, CD200, with markers for cancer stem cells. Biochem Biophys Res Commun 364:778-782
22. Gorczynski RM, Chen ZQ, Diao J et al (2010) Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice. Breast Cancer Res Treat 123:405-415
23. Gorczynski RM, Clark DA, Erin N, Khatri I (2011) Role of CD200 expression in regulation of metastasis of EMT6 tumor cells in mice. Breast Cancer Res Treat 130:49-60
24. Gorczynski RM, Chen ZQ, He W et al (2009) Expression of a CD200 transgene is necessary for induction but not maintenance of tolerance to cardiac and skin allografts. J Immunol 183:1560-1568
25. Boudakov I, Liu J, Fan N, Gulay P, Wong K, Gorczynski RM (2007) Mice lacking CD200R1 show absence of suppression of lipopolysaccharide-induced tumor necrosis factor-alpha and mixed leukocyte culture responses by CD200. Transplantation 84:251-257
26. Snedecor GW, Cochrane WG. (1971) In Statistical methods, 6th edn, Iowa State University Press, Amres, Iowa, pp 135-160
27. Skalova K, Mollova K, Michalek J (2010) Human myeloid dendritic cells for cancer therapy: does maturation matter? Vaccine 28:5153-5160
28. Walser TC, Ma XR, Kundu N, Dorsey R, Goloubeva O, Fulton AM (2007) Immune-mediated modulation of breast cancer growth and metastasis by the chemokine mig (CXCL9) in a murine model. J Immunother 30:490-498
29. Baumgartner J, Wilson C, Palmer B, Richter D, Banerjee A, McCarter M (2007) Melanoma induces immunosuppression by up-regulating FOXP3(+) regulatory T cells. J Surg Res 141:72-77
30. Hilchey SP, De A, Rimsza LM, Bankert RB, Bernstein SH (2007) Follicular lymphoma intratumoral CD4(+)CD25(+)GITR(+) regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8(+)CD25(-) and CD4(+)CD25(-) T cells. J Immunol 178:4051-4061
31. DiazMontero CM, Salem ML, Nishimura MI, GarrettMayer E, Cole DJ, Montero AJ (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58:49-59
32. Bierie B, Moses HL (2010) Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev 21:49-59
33. Hori S (2010) Developmental plasticity of Foxp3(+) regulatory T cells. Curr Opin Immunol 22:575-582
34. deLeeuw RJ, Kost SE, Kakal JA, Nelson BH (2012) The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res 18:3022-3029